To explore the potential of the skin microbiome as biomarker in six dermatological conditions: atopic dermatitis (AD), acne vulgaris (AV), psoriasis vulgaris (PV), hidradenitis suppurativa (HS), seborrhoeic dermatitis/pityriasis capitis (SD/PC) and ulcus cruris (UC).
Introduction
The escalating number of therapeutic candidates in drug development programs require strategies that optimize the process of clinical development. A common approach is the use of biomarkers in clinical trials. A biomarker is defined as a characteristic that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention [1, 2] . Clinical biomarkers are thought to reflect disease activity and pathophysiology [3, 4] . A useful biomarker in any class has to comply with the following general criteria: (i) there must be a consistent response of the biomarker across studies (preferably from different research groups) and drugs from the same mechanistic class; (ii) the biomarker must respond clearly to therapeutic (not supratherapeutic) doses; (iii) there must be a clear dose-or concentration-response relationship; and (iv) there must a plausible relationship between the biomarker, pharmacology of the drug class and disease pathophysiology [4] . Validated biomarkers are often being used to guide drug development programmes from human pharmacology studies, i.e. phase 1 trials, to confirmatory trials, i.e. phase 3 studies [2] . For dermatological diseases the drug developers often rely on clinical efficacy scores, e.g. the Eczema Area and Severity Index (EASI) for atopic dermatitis (AD), Psoriasis Area and Severity Index for psoriasis vulgaris (PV) and inflammatory lesion count for acne vulgaris (AV) or investigator global assessments. However, more objective outcome measures including validated biomarkers would have great added value in this field. One of these potential new biomarkers is the human skin microbiome, which has the potential to monitor disease activity and drug specific (mechanistic) effects.
The human microbiome refers to the combined genomic information of all microbial communities living on or in the human body. Collectively, this encompasses fungi (mycobiota), bacteria (microbiota), viruses, bacteriophage, archaea and protozoa. This, along with the human genome, completes what is now termed the human microbial superorganism [5] . The skin microbiome harbours vast microbial communities living in a range of both physiologically and topographically distinct niches and microenvironments [6, 7] . Actinobacteria (52%), Firmicutes (24%), Proteobacteria (17%) and Bacteroidetes (7%) are the four most abundant species identified on the skin [8] . Previous studies have shown that it is not only skin topography that influences microbial colonization, but also a vast range of host-specific factors including age and sex, and environmental factors such as occupation, clothing choice, antibiotic use, cosmetics, soaps, environmental temperature, humidity, and longitudinal and/or latitudinal variation in UV exposure, which can all contribute to the variability seen in the microbial flora of the skin [9] [10] [11] [12] [13] [14] [15] . Moreover, changes or aberrations in the skin microbiome have been implicated in the pathophysiology of numerous skin diseases such as AD and AV [16] .
Several reviews have described the role and impact of skin microbiome on disease [17] [18] [19] [20] [21] [22] . However, to date, no structured review has been conducted to evaluate the feasibility, suitability and potential use of the skin microbiome as biomarker for early phase clinical drug development. Therefore, we conducted a systemic literature review with predefined search terms according to the PRISMA guidelines, with focus on six relevant disorders, i.e. AD, seborrhoeic dermatitis and pityriasis capitis (dandruff; SD/PC), AV, hidradenitis suppurativa (HS), PV and ulcus cruris/chronic wounds (UC). In addition, we evaluated and ranked the conditions regarding the potential as clinical biomarker. Lastly, we provided recommendations for prospective microbiome investigations in clinical drug development programmes.
Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) [23] . In collaboration with a trained librarian from the Leiden University Medical Centre, a structured electronic literature search was composed, using a combination of two main search criteria: microbiome and the targeted skin condition (i.e. AD, SD/PC, HS, AV, UC and PV). For each search term, all relevant keyword variations were used in conjunction with free text word variations. The search strategy was optimized for all consulted databases, taking into account the differences of the various controlled vocabularies, as well as the differences of database-specific technical variations (e.g. the use of quotation marks). The final search was performed on 29 September 2017, using bibliographic databases including PubMed (incl. MEDLINE), Embase (OVID-version), Web of Science, Cochrane Library, CENTRAL, Academic Search Premier and ScienceDirect. Animal-only studies, reviews without original data, nonEnglish studies and case studies were excluded. Moreover, culture-based methods were excluded since the objective of this review was to explore the full microbiome profile and relative abundances compared to other genus as biomarker. The remaining studies were fully reviewed. The overall quality of evidence was rated using pre-defined criteria (group size, type of control, method of sampling, serial sampling available, well defined metadata, analysis method). Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines were used as guidance for rating the quality of evidence [24] . This was done by two investigators independently and the final outcome was determined by discussion once discrepancies occurred.
Results
The search resulted in 841 titles. After duplicates were removed, 443 papers were screened for inclusion. Fourhundred-and-one manuscripts were excluded based on the exclusion criteria with mostly culture-based studies that were not eligible. The remaining 42 studies were identified as using nonculture-based methods to analyse microbiome populations in one of the targeted skin conditions and fully reviewed, Figure 1 . All 42 were included in the review, the study characteristics can be found in Table 1 .
Psoriasis vulgaris
In 10 studies, the cutaneous microbiome in PV patients was investigated, Table 1 [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . In addition to microbiota, these studies have focused on the mycobiota. An increased A systematic literature review of the human skin microbiome as biomarker for dermatological drug development diversity in the fungal flora in psoriatic skin lesions, compared to healthy skin was reported by Paulino et al. [25] and Amaya et al. [26] . No differences in the abundance of specific species was observed. Controversially, a significant dichotomy between the relative abundances of specific Malassezia species between healthy skin, and psoriatic skin lesions was found by Takemoto et al. [32] . Similar inconsistencies in findings were also observed in those studies assessing the microbiota [28] [29] [30] [31] 34] .
Hidradenitis suppurativa
To date, only two studies have been published that investigated the skin microbiome in HS (Table 1 ) [35, 36] . Both studies report a significant dysbiosis in HS lesional skin with more abundance of anaerobic genera. Five lesional microbiome types were identified of which type 1 (Corynebacterium species) and type IV (Porphyromonas and Peptoniphilus species) were most prevalent [35] . Porphyromonas was also found as predominantly abundant on lesional skin by Guet-Revillet et al. [36] , together with Prevotella species. In addition, clinical severity significantly correlated with Fusobacterium and Parvimonas species variation in this study.
Ulcus cruris
The role of the skin microbiome in UC was explored in 10 different studies, Table 1 [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . Current research into UC microbiome, comprises larger, longitudinal studies, compared to those in PV and HS. The skin mycobiota of diabetic foot ulcers was longitudinally assessed and was observed to be highly heterogeneous over time and between subjects while the diversity increased upon antibiotic treatment [45] .
There have been similar efforts to reveal correlations between patient metadata, treatment and/or clinical outcomes and the cutaneous microbiome in studies investigating the microbiota in UC [38, [42] [43] [44] 46] . Overall, the most common found genus in these studies was Staphylococcus, with Staphylococcus aureus the most common species. Ulcer closing in diabetic patients was found to be positively correlated with higher microbial diversity and relative abundance of Proteobacteria, while a relative abundance of Staphylococcus was correlated negatively in a study by Gardner et al. [42] . Although Staphylococcus was consistently reported to be the most common genus, inconsistencies exist regarding other genus that are important in CU.
Seborrheic dermatitis/Pityriasis capitis
Four case-control studies investigated the microbiome in SD patients [47] [48] [49] [50] , Table 1 . In general, Malassezia spp. were found to be more abundant on dandruff scalp compared to healthy scalp [47, 48, 50] . In addition to the mycobiota, a dysbiosis in Staphylococcus and Propionibacterium spp. was described in microbiota analysis [48, 50] . One of the four studies did not find a general association between Malassezia spp. and SD but did find a higher abundance of M. globate in severe SD patients [49] .
Acne vulgaris
Five studies investigated the skin microbiome in patients with AV, Table 1 [ [51] [52] [53] [54] [55] . Three (3) were case-control studies and two (2) were small single-centre, controlled studies, of whom one was a double-blind, randomized-controlled trial.
In general, all case-control studies demonstrated similarly an increased microbial abundance of Propionibacterium acnes in the skin microbiome of patients with AV, compared to healthy [51] [52] [53] . In addition, an association between a specific P. acnes strains and acne affected skin, and healthy skin respectively was demonstrated [51, 52] . Acne improved and Propionibacterium abundance decreased after various treatments, together with an increase of microbial diversity in the two controlled studies. Moreover, a positive correlation between Propionibacterium abundance and acne severity grade was found [54, 55] .
Atopic dermatitis
The skin microbiome in patients with AD was assessed in 11 studies, Table 1 [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] . A greater proportion of longitudinal studies and 2 completed randomized controlled trials were performed in AD patients. There is general consensus across studies that skin affected by AD exhibits decreased bacterial diversity, as a result of an increased abundance of S. aureus [60] [61] [62] [63] [64] 66] . In particular, AD flare ups were associated with an increased proportion of Staphyloccocus sequences, and S. aureus abundance correlated with disease severity [60] . In line with these results, microbial diversity in AD lesions was inversely correlated with overall eczema severity as observed by the EASI [63] , with several further studies also reporting taxonomic normalization and increased bacterial diversity in AD lesional skin, following various treatments [60, 61, 63, 66] .
Figure 1
Flowchart of the study T. Niemeyer -van der Kolk et al.
Table 1
Summary A systematic literature review of the human skin microbiome as biomarker for dermatological drug development T. Niemeyer -van der Kolk et al. A systematic literature review of the human skin microbiome as biomarker for dermatological drug development T. Niemeyer -van der Kolk et al. A systematic literature review of the human skin microbiome as biomarker for dermatological drug development T. Niemeyer -van der Kolk et al. A systematic literature review of the human skin microbiome as biomarker for dermatological drug development 
Discussion
This systematic review provides an overview of the clinical studies that have investigated nonculture skin microbiome associated outcomes in AD, SD, AV, HS, PV and UC with the goal to explore its potential as biomarker in early phase clinical drug development with drug specific or disease specific application, as also referred to as type 3 or type 6 biomarker according to the classic definition of Danhof et al. [67] .
Potential for microbiome as biomarker: AD and AV
From our analysis, there is some preliminary evidence that the skin microbiota may be a suitable disease specific biomarker for clinical trials of AD. This is due to the correlation between Staphylococcus abundance, microbiome diversity profile and disease severity that seems to exist in multiple trials, therewith complying with most of the criteria for a useful biomarker, Table 2 [4] . Objective data on the change of the microbiota may be valuable to support subjective AD efficacy scores in early phase clinical trials. However, it must be noted that the cause and effect relationship between skin microbiota dysbiosis and AD remains incompletely elucidated [68] . Currently, no evidence of benefit of antimicrobial interventions directed at reduction of Staphylococcus in patients with AD exists, only in secondarily impetiginized AD [69] [70] [71] . As multiple studies included in this review indicate that the skin microbiota within an individual patient varies over time [60, 61, 63, 64] , there is need for longitudinal, frequent sampling and standard analysis studies. Nevertheless, it has proven its potential value and is recommended to apply in AD clinical trials, in particular when microbiota can serve also as drugspecific biomarker, i.e. for drugs with antimicrobial activity such as antimicrobial peptides that are currently in clinical trials for AD. In AV, a strong, positive correlation between Propionibacterium and acne severity grade is reported [55] . Moreover, acne improved and Propionibacterium decreased after treatment, while the microbial diversity increased [54, 55] . Taking into account that a clear pathophysiological role of P. acnes exists and antimicrobial interventions are effective in AV [72, 73] , the adoption of the skin microbiome as biomarker in acne drug development programmes is, although still in its infancy, suggested by our review (Table 2) . Lesion clearance often takes a long time; therefore, the inclusion of microbiota is a valid option to monitor subclinical treatment effects and restoration of normal bacterial profile, i.e. rebiosis. Although a small uncertainty remains regarding the exact relationship between aberrations in the skin microbiome and acne [74] , we conclude that there is definitely a potential for the microbiota as biomarker in clinical trials (Table 2) . Another option would be to culture P. acnes instead of profiling the whole skin microbiota in clinical trials; however, with this approach a comprehensive overview and insight in the diversity will be missed.
PV, UC, hidradenitis and SD are lacking evidence
Although dysbiosis in psoriasis seems to exist in the micro-as well as the mycobiota, study findings are heterogeneous. Wide variability in study design, sampling methods, controllable factors and sequencing techniques between groups, in conjunction with small sample populations, could provide a possible explanation for this. Therefore, no clear recommendations can be made at this time. Future work focusing on serial sampling and longitudinal studying of skin microbiome populations it PV patients, may provide information on its potential applicability as biomarker, Table 2 . From a clinical perspective, we know that antimicrobial and antifungal agents are not successful in the treatment of psoriasis, which suggests that it is less attractive to explore [75, 76] . However, since immune dysregulation is the key of psoriasis and recent investigations describe the extensive cross talk between the immune system and the microbiome, there may still be potential that should be explored [77] . For UC inconsistencies in study design, sampling methods and the heterogeneity of the disease group also limit the comparability of study findings. There appears to be a relationship between certain species, types of ulcers and ulcer duration [42, 46] . However, longitudinal studies with frequent standard sampling and A systematic literature review of the human skin microbiome as biomarker for dermatological drug development standard analysis procedures are necessary to make a recommendation. The finding of dysbiosis in HS skin microbiome mostly regarding anaerobic species that is mostly consistent in two different studies opens up opportunities for the skin microbiome as biomarker in this field, Table 2 [35, 36] . However, future studies will have to confirm this potential. In SD, three different sequencing methods were used in the three different studies [47, 49, 50] . This, together with the small sample populations, single time point sampling and poor study designs, might explain the heterogeneity in findings.
Since there is a clear evidence that antifungal agents such as ketoconazole are effective in SD [78] , it is recommended to further explore the skin microbiome's potential in this disease in future clinical trials.
Limitations and considerations
It is important to note that in all included studies, there was a high variability in study design and sampling methods between groups, which makes comparisons of specific findings difficult. Case-control studies (25/42, 60%) dominate research into the skin microbiome and skin disease. Patients are compared with healthy controls, capturing microbial profiles at a particular time, but have little predictive value in determining functionality, looking more at associations, and not causation. The small patient sample sizes across all studies may fail to account for interindividual differences within the study population. The poorly defined inclusion and exclusion criteria, with certain studies including actively treated patients in their sample population, could also confound potential findings. The standardization of controllable factors to reduce confounders was not well documented or maybe not performed in most of the included studies. As simple factors including but not limiting of age, ethnicity, environmental factors, soap use, hand-washing and the use of topical (antimicrobial) agents before sampling have been shown to alter microbial skin communities; documentation of these metadata is essential to draw valid conclusions [5, 8, 12, 60, 61, [79] [80] [81] . Multiple methods were used for skin microbiome sampling across the studies (i.e. swabs, biopsies, tape strips, wound curettes). Interestingly, all have been shown to exhibit a wide variation in biomass yield, microbial profile, human DNA contribution/contamination, sampling depth and discomfort level for the test subject [19, 62, [82] [83] [84] [85] [86] [87] . In addition to the sampling method, the selection of sampling sites and sampling frequency are important factors that were not always considered in the included studies. Consistent sampling of the same anatomical area of skin in all individuals in study cohorts is essential in order to limit confounders, and allow for the accurate comparison of skin microbiome populations. Moreover, regarding analysis, only consistent use of specific primers to target specific hypervariable V regions, will allow for collation of data and comparison between multiple studies. It is clear that broadly used analysis methods in this review as shown in Table 1 count as a limitation for comparison. Taken all the above together, based on the level of evidence it is clear that our recommendations should be made with some caution. A standard approach for skin microbiome study design, collection, storage, processing and analysis as proposed by Kong et al. should be followed in future studies [17] . However, although the list of limitations and sometimes poor evidence might be assessed as a weak recommen dation for the inclusion of cutaneous microbiome in dermatological trials, the recent finding that the gut microbiome partially explains the response/nonresponse to PD-1 immunotherapy in different cancer patients will foster research into microbiome in general [88, 89] . In addition, the relation between the gut microbiome in inflammatory bowel disease and response to infliximab was also recently highlighted [90] . In particular, when considering the reports about the role of the gut-skin axis that might influence many diseases including the here investigated skin disorders [91] [92] [93] .
Conclusion
Only a small number of studies have consistently reported the cutaneous microbiome for skin diseases and chronic wounds. Our findings reveal that for two indications -AD and AV -there is preliminary evidence to support implementation of the skin microbiome as biomarker in early phase clinical trials. For PV, UC, SD and HS, there is insufficient evidence. More standardized microbiome-directed studies studying the effect of current treatments on the microbiome are needed to draw conclusions.
